Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy
⚠️
Other active recalls for Glycerin (different manufacturers) — 4 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Apr 27, 2026 — Lack of Assurance of Sterility: The recall is being initiated out of an abundance of caution following FDA observations noted during a recent inspection of Excelvision. (Oasis Medical, Inc.)· FDA recall D-0525-2026
Class II · Apr 20, 2026 — Lack of Assurance of Sterility (SCOPE HEALTH)· FDA recall D-0499-2026
Class II · Mar 25, 2026 — Lack of Assurance of Sterility (Preferred Pharmaceuticals, Inc.)· FDA recall D-0443-2026
Class II · Mar 3, 2026 — Lack of Assurance of Sterility (K.C. Pharmaceuticals, Inc)· FDA recall D-0411-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Established class (EPC)Non-Standardized Chemical Allergen
Physiologic effectIncreased Histamine Release; Cell-mediated Immunity; Increased IgG Production
Chemical classAllergens; Glycerol
DEA scheduleNon-controlled
Marketing categoryOTC MONOGRAPH DRUG
Marketing statusOn market
FDA listing statusListed (active directory)
Marketing start2019-01-02
RouteRECTAL
Dosage formSUPPOSITORY
SubstanceGLYCERIN
GPI-1446600010005206
GPI classGlycerin Childrens
GCN Seq No011729
GCN08861
HICL code001312
Ingredient (HICL)Glycerin
HIC1 codeQ
Therapeutic class — broad (HIC1)Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 codeQ3
Therapeutic class — intermediate (HIC2)Anal-Rectal Preparations
HIC3 codeQ3S
Therapeutic class — specific (HIC3)Laxatives, Local/Rectal
AHFS code56:12.00.00
AHFS classCathartics And Laxatives
FDB label nameCHILD GLYCERIN SUPPOSITORY
FDB brand nameGlycerin
Legend statusO — Over-the-counter (OTC) drug or device
Why two NDCs?
The FDA registers this code as 70000-0429-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70000-0429-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️RxNorm drug class
This medicine belongs to the Non-Standardized Chemical Allergen class.
Pharmacologic classNon-Standardized Chemical Allergen
Drug family (ATC)Enemas, Other drugs for constipation
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
Label name CHILD GLYCERIN SUPPOSITORYIngredient Glycerin
🧪 What is this product?
This is a rectal suppository containing glycerin, an over-the-counter product sold under FDA's monograph rules for its drug category. Glycerin in suppository form is commonly used as an osmotic agent to help soften stool and promote bowel movements. The suppository dissolves when inserted into the rectum, allowing the glycerin to work locally in the lower digestive tract. This product type is typically used by people seeking occasional constipation relief.
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Glycerin?
Ask a licensed pharmacist directly — free, answered by our team.
Inactive ingredients, also called excipients, are components of the drug product
other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors,
or other formulation ingredients.
Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
Price system
Per ea
Per package
Retail pharmacies payNADAC · weekly
$0.101
$2.52 / 25 suppositories
Medicaid paysCMS SDUD · 12 mo
$0.5097
$12.74 / 25 suppositories
Medicare drug plans payPart D · quarterly
No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
▲ Up 82% over the last 16 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2019
On the market since
Jan 2019
📍
2026
Currently FDA-listed
7 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
🗺️ Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 70000-0429-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.7K
Units reimbursed last 4 qtrs
81.8K
Gross reimbursed last 4 qtrs
$41.7K
Avg / prescription
$11.25
Avg / unit
$0.5097
Latest quarter Q4 2025
806Rx
Medicaid pays / ea
$0.5097
gross reimbursed
vs
NADAC / ea
$0.1009
acquisition cost
=
Spread
+$0.4088
+405% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
81% FFS19% MCO
Fee-for-service · 2,998 Rx Managed care · 707 Rx
State Medicaid map
Units reimbursed · per 100k residents
6.6294
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
1New York294 /100k
2Delaware124 /100k
3Kentucky62.7 /100k
4New Jersey61.5 /100k
5Washington27.0 /100k
6California21.9 /100k
7Pennsylvania15.9 /100k
8Arizona15.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Glycerin — the ingredient across all brands.
Top reported reactions
Oral Herpes2,427
Condition Aggravated2,018
Eye Irritation1,068
Eye Pain1,013
Incorrect Drug Administration Duration806
Pain758
Herpes Simplex709
Age at onset
Neonate3
Infant11
Child22
Adolescent14
Adult831
Elderly1,496
Reporter sex
Male · 27%
Female · 73%
Unknown · 0%
Serious outcomes
Hospitalization2,612
Death681
Life-threatening414
Disabling225
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
Package NDC
Description
Marketing start
Status
70000-0429-01 You're viewing this
25 SUPPOSITORY in 1 JAR (70000-0429-1)
2019-01-02
Active
📄 FDA label — Drug Facts FDA SPL
The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
Uses for relief of occassional constipation this product generally produces bowel movement in 1/4 to 1 hour
⏱️Dosage and Administration42 words▾
Directions - single daily dose children 2 to under 6 years - 1 suppository, or as directed by a doctor chidren under 2 - ask a doctor Insert suppository well up into rectum. Suppository need not melt completely to produce laxative action.
⚠️Warnings94 words▾
Warnings For rectal use only May cause rectal discomfort or a burning sensation. Ask a doctor before using any laxative if child has abdominal pain, nausea or vomiting a sudden change in bowel habits lasting more than 2 weeks already used a laxative formore than 1 week Stop use and consult a doctor if child has rectal bleeding no bowel movement within 1 hour using this product These symptoms may indicate a serious condition. Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
🧪Active Ingredient7 words▾
Active ingredient (in each suppository) Glycerin 1g
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.